Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor ...

Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157 achieved a breakthrough in Phase 3 trials, triggering a sharp ...

The latest international Christy Santhosh news and views from Reuters - one of the world's largest news agencies ...

The Moderna result strengthens the strategic connection behind the Personalis deal, but it does not validate the entire ...

Here are Cathie Wood’s latest moves.

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major ...

Tempus AI stock surged this week after Merck and Moderna published encouraging trial results for a cancer treatment. A company that Tempus AI is acquiring provided technologies that aided the ...

Tempus has been trading back and forth on fears of AI replacing the precision medicine company to provide a tailwind to drug discovery and the use of foundational models to boost data licensing. The ...

This routine divestment occurred as the stock reflected a -27% return over the 12 months ending August 14, before a major stock surge. Chicago-based Tempus AI operates a healthcare technology platform ...

The transaction involved 41,095 shares executed at a weighted average price of $49.61 per share, representing a total value of $2.0 million. The sale was non-discretionary, executed to cover tax ...

The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units. Post-transaction, the insider maintains a direct ...